Selection of aptamers against the Jagged-1 protein
DOI:
https://doi.org/10.15392/2319-0612.2022.1933Keywords:
Breast cancer, aptamer, Jagged-1Abstract
The breast cancer is one of the biggest public health problems in the world, being the main female type of cancer that affects the population. The Jagged-1 protein plays an important role in the biology and development of cancer, influencing angiogenesis, growth of neoplastic cells, tumor stem cells, epithelial mesenchymal transition, metastatic processes and resistance to therapies in various types of cancer. In this project, our aim was to select an aptamer for JAG1 ligand using an aptamer library, that could be used as a radiopharmaceutical for PET / SPECT / CT diagnosis of tumors that express JAG1. Our work showed that MDA-MB-231-JAG1 cells overexpress more mRNA and JAG1 protein than control cells (MDA-MB-231-Control). We also selected aptamers with high affinity for MDA-MB-231-JAG1 cells that could be a useful tool for the development of new radiopharmaceuticals for the diagnosis and treatment of tumors that overexpress JAG1.
Downloads
References
MS/INCA, “Estimativa de Câncer no Brasil, 2020,” 2020. https://www.inca.gov.br/numeros-de-cancer.
WHO, “Cancer,” World Health Organization, 2020.
C. Guarnaccia, A. Pintar, and S. Pongor, “Exon 6 of human Jagged-1 encodes an autonomously folding unit,” FEBS Lett., 2004. DOI: https://doi.org/10.1016/j.febslet.2004.08.022
Oda, T., Elkahloun, A.G., Pike, B.L., Okajima, K., Krantz, I.D., Genin, A., Piccoli, D.A., Meltzer, P.S., Spinner, N.B., Collins, F.S., Chandrasekharappa, S.C.,Oda, T., Elkahloun, A.G., Pike, B.L., Okajima, K., Krantz, I.D., Genin, A., Piccoli, D.A., Melt, “Mutations in the human Jagged1 gene are responsible for Alagille syndrome,” Nat. Genet., vol. 16, pp. 235–242, 1997. DOI: https://doi.org/10.1038/ng0797-235
M. Gijs, A. Aerts, N. Impens, S. Baatout, and A. Luxen, “Aptamers as radiopharmaceuticals for nuclear imaging and therapy,” Nucl. Med. Biol., vol. 43, no. 4, pp. 253–271, 2016, doi: 10.1016/j.nucmedbio.2015.09.005. DOI: https://doi.org/10.1016/j.nucmedbio.2015.09.005
P. J. Bates, E. M. Reyes-reyes, M. T. Malik, E. M. Murphy, M. G. O. Toole, and J. O. Trent, “G-quadruplex oligonucleotide AS1411 as a cancer-targeting agent : Uses and mechanisms,” Biochim. Biophys. Acta, vol. 1861, no. 5, pp. 1414–1428, 2017, doi: 10.1016/j.bbagen.2016.12.015. DOI: https://doi.org/10.1016/j.bbagen.2016.12.015
C. E. B. De Almeida, L. Nascimento, H. F. Rocha, J. B. Cabral-neto, and S. Missailidis, “Aptamer delivery of siRNA , radiopharmaceutics and chemotherapy agents in cancer,” Int. J. Pharm., vol. 525, no. 2, pp. 334–342, 2017, doi: 10.1016/j.ijpharm.2017.03.086. DOI: https://doi.org/10.1016/j.ijpharm.2017.03.086
F. Maleki, F. Rezazadeh, and K. Varmira, “MUC1-Targeted Radiopharmaceuticals in Cancer Imaging and Therapy,” 2021, doi: 10.1021/acs.molpharmaceut.0c01249. DOI: https://doi.org/10.1021/acs.molpharmaceut.0c01249
Published
Issue
Section
License
Copyright (c) 2022 Brazilian Journal of Radiation Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing: The BJRS articles are licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
How to Cite
